MedTrace Logo

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

NCT00143741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-01-10

No results posted yet for this study

Summary

The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients to decrease the antibodies in such a way, that it may become possible to safely transplant kidneys into them.

Conditions

  • End-Stage Kidney Disease

Interventions

DRUG

Atorvastatin (Lipitor)

20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Pradeep Kadambi, MD · The University of Chicago, 5841 South Maryland Ave., MC 5100 Chicago, IL 60637

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2010-12-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143741 on ClinicalTrials.gov